Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 2;13:9839–9848. doi: 10.2147/OTT.S253691

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tong et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

(A) Inhibition rate of proliferation of Panc-1 (parental cell line) and Panc-1/Gem (gemcitabine-.resistant cell line); (B) Inhibition rate of proliferation of MIA-PaCa-2 (parental cell line) and MIA-PaCa-2/Gem (gemcitabine-resistant cell line). (C) Cell viability of Panc-1 and Panc-1/Gem cells after 72 hours of emodin application at different concentrations detected by MTT assay. (D) Cell viability of MIA-PaCa-2 and MIA-PaCa-2/Gem cells after 72 hours of emodin application at different concentrations detected by MTT assay. (E) Cell viability of all cell lines after 72 hours of treatment from all groups (emodin 40 μM, gemcitabine 20 μM). *P< 0.05.